Skip to main content
. 2016 Jun 14;7(28):44252–44265. doi: 10.18632/oncotarget.10020

Figure 4. miR-22 suppresses tumor growth and metastasis in animal models of osteosarcoma and prostate cancer.

Figure 4

A and G. Representative bioluminescence images of mice with the orthotopic osteosarcoma model and xenografts of prostate cancer. Animals were imaged and treated with an intratumoral injection of miR-22 or NC miRNA every week until the date of death. C and I. Peak of bioluminescence (CPS) of the NC and miR-22 treatment groups were compared in the tumor-bearing mice (*P<0.05, **P<0.01). When the mice died or got sacrificed, the tumors were excised, photographed B and H. and weighed D and J. (**P<0.01), and the mice organs (Lu, Lung; Li, Liver; Sp, Spleen; Ki, Kidney; In, Intestine) were taken out for bioluminescence imaging F and L. The survival time of the mice with treatments of NC or miR-22 were analyzed by a Kaplan-Meier curve E and K. Finally, the tumor tissues were examined by H&E or IHC staining (100X, scale bar 200 μm) M and N.